The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Open accessAbstract
Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype with poor prognosis. We sequenced 29 SCLC exomes, 2 genomes and 15 transcriptomes and found an extremely high mutation rate of 7.4 ± 1 protein-changing mutations per million base pairs. Therefore, we conducted integrated analyses of the various data sets to identify pathogenetically relevant mutated genes. In all cases, we found evidence for inactivation of TP53 and RB1 and identified recurrent mutations in the CREBBP, EP300 and MLL genes that encode histone modifiers. Furthermore, we observed mutations in PTEN, SLIT2 and EPHA7, as well as focal amplifications of the FGFR1 tyrosine kinase gene. Finally, we detected many of the alterations found in humans in SCLC tumors from Tp53 and Rb1 double knockout mice. Our study implicates histone modification as a major feature of SCLC, reveals potentially therapeutically tractable genomic alterations and provides a generalizable framework for the identification of biologically relevant genes in the context of high mutational background.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [9]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
SIFT: predicting amino acid changes that affect protein function
Ng, P. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg509 · Cited by 6,577
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citation
Cited by
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Comprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340
Self-citationUsing Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Self-citationRudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Self-citationExtracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
Lessons from the Cancer Genome
Garraway, L. A., & Lander, E. S. (2013) · Cell · doi:10.1016/j.cell.2013.03.002 · Cited by 1,308
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E., Lehman, J. M., MacPherson, D., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,254
Self-citationDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Self-citationRindi, G., Klimstra, D. S., Abedi-Ardekani, B., Asa, S. L., Bosman, F. T., Brambilla, E., Busam, K. J., de Krijger, R. R., Dietel, M., El-Naggar, A. K., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0110-y · Cited by 1,163
Self-citationOser, M. G., Niederst, M. J., Sequist, L. V., & Engelman, J. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71180-5 · Cited by 942
Bueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Self-citationSmall-cell lung cancer: what we know, what we need to know and the path forward
Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.87 · Cited by 904
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
Feinberg, A. P., Koldobskiy, M. A., & Göndör, A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.13 · Cited by 841
The world of protein acetylation
Drazic, A., Myklebust, L. M., Ree, R., & Arnesen, T. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.06.007 · Cited by 804
Advances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.8 · Cited by 799
Genetic landscape of esophageal squamous cell carcinoma
Gao, Y.-B., Chen, Z.-L., Li, J.-G., Hu, X.-D., Shi, X.-J., Sun, Z.-M., Zhang, F., Zhao, Z.-R., Li, Z.-T., Liu, Z.-Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.3076 · Cited by 694
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Hodgkinson, C. L., Morrow, C. J., Li, Y., Metcalf, R. L., Rothwell, D. G., Trapani, F., Polanski, R., Burt, D. J., Simpson, K. L., Morris, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3600 · Cited by 694
Hijacked in cancer: the KMT2 (MLL) family of methyltransferases
Rao, R. C., & Dou, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3929 · Cited by 669
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms7377 · Cited by 647
Self-citationSmall cell lung cancer: Where do we go from here?
Byers, L. A., & Rudin, C. M. (2015) · Cancer · doi:10.1002/cncr.29098 · Cited by 636
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
Mack, S. C., Witt, H., Piro, R. M., Gu, L., Zuyderduyn, S., Stütz, A. M., Wang, X., Gallo, M., Garzia, L., Zayne, K., et al. (2014) · Nature · doi:10.1038/nature13108 · Cited by 607
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 607
Mollaoglu, G., Guthrie, M. R., Böhm, S., Brägelmann, J., Can, I., Ballieu, P. M., Marx, A., George, J., Heinen, C., Chalishazar, M. D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.005 · Cited by 588
Self-citationFunctions of bromodomain-containing proteins and their roles in homeostasis and cancer
Fujisawa, T., & Filippakopoulos, P. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.143 · Cited by 573
Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers
Supek, F., Miñana, B., Valcárcel, J., Gabaldón, T., & Lehner, B. (2014) · Cell · doi:10.1016/j.cell.2014.01.051 · Cited by 557
Reck, M., Luft, A., Szczesna, A., Havel, L., Kim, S.-W., Akerley, W., Pietanza, M. C., Wu, Y.-L., Zielinski, C., Thomas, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6601 · Cited by 538
Targeting FGFR Signaling in Cancer
Touat, M., Ileana, E., Postel-Vinay, S., André, F., & Soria, J.-C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2329 · Cited by 524
Self-citationBaine, M. K., Hsieh, M.-S., Lai, W. V., Egger, J. V., Jungbluth, A. A., Daneshbod, Y., Beras, A., Spencer, R., Lopardo, J., Bodd, F., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.009 · Cited by 522
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
Ireland, A. S., Micinski, A. M., Kastner, D. W., Guo, B., Wait, S. J., Spainhower, K. B., Conley, C. C., Chen, O. S., Guthrie, M. R., Soltero, D., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.001 · Cited by 508
Lee, J.-K., Lee, J., Kim, S., Kim, S., Youk, J., Park, S., An, Y., Keam, B., Kim, D.-W., Heo, D. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9096 · Cited by 505
Self-citationA DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC
Mohammad, H. P., Smitheman, K. N., Kamat, C. D., Soong, D., Federowicz, K. E., Van Aller, G. S., Schneck, J. L., Carson, J. D., Liu, Y., Butticello, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.002 · Cited by 504
Borromeo, M. D., Savage, T. K., Kollipara, R. K., He, M., Augustyn, A., Osborne, J. K., Girard, L., Minna, J. D., Gazdar, A. F., Cobb, M. H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.081 · Cited by 503
Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
Inamura, K. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00193 · Cited by 503
Unravelling the biology of SCLC: implications for therapy
Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T., & Rudin, C. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.71 · Cited by 490
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes
Alexandrov, L. B., & Stratton, M. R. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.014 · Cited by 488
New and emerging targeted treatments in advanced non-small-cell lung cancer
Hirsch, F. R., Suda, K., Wiens, J., & Bunn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31473-8 · Cited by 487
Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0015 · Cited by 455
Ni, X., Zhuo, M., Su, Z., Duan, J., Gao, Y., Wang, Z., Zong, C., Bai, H., Chapman, A. R., Zhao, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320659110 · Cited by 454
Plass, C., Pfister, S. M., Lindroth, A. M., Bogatyrova, O., Claus, R., & Lichter, P. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3554 · Cited by 453
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81603 · Cited by 444
Self-citationTargeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N., Abraham, B. J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 439
Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J., Gandhi, L., Ganti, A. K. P., Govindan, R., Grecula, J. C., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0011 · Cited by 436
Eph Receptor Signaling and Ephrins
Lisabeth, E. M., Falivelli, G., & Pasquale, E. B. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009159 · Cited by 425
Qaddoumi, I., Orisme, W., Wen, J., Santiago, T., Gupta, K., Dalton, J. D., Tang, B., Haupfear, K., Punchihewa, C., Easton, J., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1539-z · Cited by 409
Genomic alterations in lung adenocarcinoma
Devarakonda, S., Morgensztern, D., & Govindan, R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00077-7 · Cited by 404
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Testa, U., Castelli, G., & Pelosi, E. (2018) · Cancers · doi:10.3390/cancers10080248 · Cited by 403
Cell Plasticity and Heterogeneity in Cancer
Marjanovic, N. D., Weinberg, R. A., & Chaffer, C. L. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.184655 · Cited by 400
Genetic alterations defining NSCLC subtypes and their therapeutic implications
Pikor, L. A., Ramnarine, V. R., Lam, S., & Lam, W. L. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.025 · Cited by 375
Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer
Polański, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., Trapani, F., Bishop, P. W., White, A., Critchlow, S. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2270 · Cited by 378
George, J., Walter, V., Peifer, M., Alexandrov, L. B., Seidel, D., Leenders, F., Maas, L., Müller, C., Dahmen, I., Delhomme, T. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03099-x · Cited by 377
Self-citationFrom Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling
Ntziachristos, P., Lim, J. S., Sage, J., & Aifantis, I. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.018 · Cited by 374
Self-citationMegyesfalvi, Z., Gay, C. M., Popper, H., Pirker, R., Ostoros, G., Heeke, S., Lang, C., Hoetzenecker, K., Schwendenwein, A., Boettiger, K., et al. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21785 · Cited by 369
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors
Francis, J. M., Kiezun, A., Ramos, A. H., Serra, S., Pedamallu, C. S., Qian, Z. R., Banck, M. S., Kanwar, R., Kulkarni, A. A., Karpathakis, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2821 · Cited by 369
Self-citationNfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility
Denny, S. K., Yang, D., Chuang, C.-H., Brady, J. J., Lim, J. S., Grüner, B. M., Chiou, S.-H., Schep, A. N., Baral, J., Hamard, C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.052 · Cited by 368
Self-citationUncovering novel mutational signatures by de novo extraction with SigProfilerExtractor
Islam, S. M. A., Díaz-Gay, M., Wu, Y., Barnes, M., Vangara, R., Bergstrom, E. N., He, Y., Vella, M., Wang, J., Teague, J. W., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100179 · Cited by 365
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A. J., Nuciforo, P., & Tabernero, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 365
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 364
Fibroblast growth factor receptors as treatment targets in clinical oncology
Katoh, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0115-y · Cited by 352
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
Tan, H.-L., Sood, A., Rahimi, H. A., Wang, W., Gupta, N., Hicks, J., Mosier, S., Gocke, C. D., Epstein, J. I., Netto, G. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1982 · Cited by 346
Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity
Wainwright, E. N., & Scaffidi, P. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.04.004 · Cited by 342
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
Fernandez-Cuesta, L., Peifer, M., Lu, X., Sun, R., Ozretić, L., Seidel, D., Zander, T., Leenders, F., George, J., Müller, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4518 · Cited by 317
Self-citationCarter, L., Rothwell, D. G., Mesquita, B., Smowton, C., Leong, H. S., Fernandez-Gutierrez, F., Li, Y., Burt, D. J., Antonello, J., Morrow, C. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4239 · Cited by 308
Mutational dynamics between primary and relapse neuroblastomas
Schramm, A., Köster, J., Assenov, Y., Althoff, K., Peifer, M., Mahlow, E., Odersky, A., Beisser, D., Ernst, C., Henssen, A. G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3349 · Cited by 304
Self-citationWT1 Recruits TET2 to Regulate Its Target Gene Expression and Suppress Leukemia Cell Proliferation
Wang, Y., Xiao, M., Chen, X., Chen, L., Xu, Y., Lv, L., Wang, P., Yang, H., Ma, S., Lin, H., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.023 · Cited by 304
Molecular biology of lung cancer.
Cooper, W. A., Lam, D. C.-L., O'Toole, S. A., & Minna, J. D. (2013) · PubMed · doi:10.3978/j.issn.2072-1439.2013.08.03 · Cited by 303
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway
Mohseni, M., Sun, J., Lau, A., Curtis, S., Goldsmith, J., Fox, V. L., Wei, C., Frazier, M., Samson, O., Wong, K.-K., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2884 · Cited by 294
CD74–NRG1 Fusions in Lung Adenocarcinoma
Fernandez-Cuesta, L., Plenker, D., Osada, H., Sun, R., Menon, R., Leenders, F., Ortiz-Cuaran, S., Peifer, M., Bos, M., Daßler, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0633 · Cited by 294
Self-citationBromodomain inhibitors and cancer therapy: From structures to applications
Pérez-Salvia, M., & Esteller, M. (2017) · Epigenetics · doi:10.1080/15592294.2016.1265710 · Cited by 292
Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing
McFadden, D. G., Papagiannakopoulos, T., Taylor-Weiner, A., Stewart, C., Carter, S. L., Cibulskis, K., Bhutkar, A., McKenna, A., Dooley, A., Vernon, A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.031 · Cited by 288
Self-citationScientific Advances in Lung Cancer 2015
Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., de Koning, H. J., Yousaf-Khan, A. U., McWilliams, A., Tsao, M. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.012 · Cited by 284
Lung cancer epigenetics: From knowledge to applications
Duruisseaux, M., & Esteller, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.005 · Cited by 283
Current Diagnosis and Management of Small-Cell Lung Cancer
Wang, S., Zimmermann, S., Parikh, K., Mansfield, A. S., & Adjei, A. A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.034 · Cited by 282
Clinical Implications of Genomic Discoveries in Lung Cancer
Swanton, C., & Govindan, R. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1504688 · Cited by 269
Grove, O., Berglund, A. E., Schabath, M. B., Aerts, H. J. W. L., Dekker, A., Wang, H., Velazquez, E. R., Lambin, P., Gu, Y., Balagurunathan, Y., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118261 · Cited by 263
“More recently, treatment strategies have begun to involve the subdivision of non-small-cell lung cancers (NSCLC) into molecular subsets based on specific driver mutational status in oncogenes and tumor suppressor genes [3,4].”
BackgroundK-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
Scheffler, M., Ihle, M. A., Hein, R., Merkelbach-Bruse, S., Scheel, A. H., Siemanowski, J., Brägelmann, J., Kron, A., Abedpour, N., Ueckeroth, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.013 · Cited by 264
Self-citationYu, H. A., Suzawa, K., Jordan, E., Zehir, A., Ni, A., Kim, R., Kris, M. G., Hellmann, M. D., Li, B. T., Somwar, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2961 · Cited by 259
WIPI proteins: essential PtdIns3 P effectors at the nascent autophagosome
Proikas-Cezanne, T., Takacs, Z., Dönnes, P., & Kohlbacher, O. (2015) · Journal of Cell Science · doi:10.1242/jcs.146258 · Cited by 253
The effects of chromatin organization on variation in mutation rates in the genome
Makova, K. D., & Hardison, R. C. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3890 · Cited by 253
Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.2007 · Cited by 233
Molecular pathways and therapeutic targets in lung cancer
Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220
“FGFR1 is the only RTK amplified at appreciable frequency (6%) in SCLC [5].”
BackgroundInfluentialCancers with wrong HATs: the impact of acetylation
Di Cerbo, V., & Schneider, R. (2013) · Briefings in Functional Genomics · doi:10.1093/bfgp/els065 · Cited by 178
Self-citationFaber, A. C., Farago, A. F., Costa, C., Dastur, A., Gomez-Caraballo, M., Robbins, R., Wagner, B. L., Rideout, W. M., Jakubik, C. T., Ham, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411848112 · Cited by 127
Understanding mutagenesis through delineation of mutational signatures in human cancer
Petljak, M., & Alexandrov, L. B. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw055 · Cited by 110
Immune and inflammatory cell composition of human lung cancer stroma
Banat, G.-A., Tretyn, A., Pullamsetti, S. S., Wilhelm, J., Weigert, A., Olesch, C., Ebel, K., Stiewe, T., Grimminger, F., Seeger, W., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139073 · Cited by 107
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Neel, D. S., & Bivona, T. G. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0007-0 · Cited by 98
RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis during DNA damage
Ho, S.-R., Mahanic, C. S., Lee, Y.-J., & Lin, W.-C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323107111 · Cited by 88
Kloth, M., Ruesseler, V., Engel, C., Koenig, K., Peifer, M., Mariotti, E., Kuenstlinger, H., Florin, A., Rommerscheidt-Fuss, U., Koitzsch, U., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-309026 · Cited by 73
Self-citationAlidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A. H., Frank, S., Holz, B., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5110 · Cited by 69
Self-citationChiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2287-9 · Cited by 64
Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer
Cargill, K. R., Stewart, C. A., Park, E. M., Ramkumar, K., Gay, C. M., Cardnell, R. J., Wang, Q., Diao, L., Shen, L., Fan, Y.-H., et al. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00270-9 · Cited by 62
The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
Synnott, N. C., Madden, S. F., Bykov, V. J. N., Crown, J., Wiman, K. G., & Duffy, M. J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.08.009 · Cited by 35
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Ho, S.-R., Lee, Y.-J., & Lin, W.-C. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645499 · Cited by 28
Metadata
- Authors
- Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., Menon, R., Koker, M., Dahmen, I., Müller, C., Di Cerbo, V., Schildhaus, H.-U., Altmüller, J., Baessmann, I., Becker, C., de Wilde, B., Vandesompele, J., Böhm, D., Ansén, S., Gabler, F., Wilkening, I., Heynck, S., Heuckmann, J. M., Lu, X., Carter, S. L., Cibulskis, K., Banerji, S., Getz, G., Park, K.-S., Rauh, D., Grütter, C., Fischer, M., Pasqualucci, L., Wright, G., Wainer, Z., Russell, P., Petersen, I., Chen, Y., Stoelben, E., Ludwig, C., Schnabel, P., Hoffmann, H., Muley, T., Brockmann, M., Engel-Riedel, W., Muscarella, L. A., Fazio, V. M., Groen, H., Timens, W., Sietsma, H., Thunnissen, E., Smit, E., Heideman, D. A. M., Snijders, P. J. F., Cappuzzo, F., Ligorio, C., Damiani, S., Field, J., Solberg, S., Brustugun, O. T., Lund-Iversen, M., Sänger, J., Clement, J. H., Soltermann, A., Moch, H., Weder, W., Solomon, B., Soria, J.-C., Validire, P., Besse, B., Brambilla, E., Brambilla, C., Lantuejoul, S., Lorimier, P., Schneider, P. M., Hallek, M., Pao, W., Meyerson, M., Sage, J., Shendure, J., Schneider, R., Büttner, R., Wolf, J., Nürnberg, P., Perner, S., Heukamp, L. C., Brindle, P. K., Haas, S., & Thomas, R. K.
- Venue
- Nature Genetics
- Published
- 2012-09-02
- Volume
- 44
- Issue
- 10
- Pages
- 1104-1110
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2108927999
- Cited by
- 1,397
- References
- 85
- FWCI
- 44.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.